SynthesisFrontiers in immunology2026

Efficacy and safety of combination versus single-agent immunotherapy for BCG-unresponsive non-muscle-invasive bladder cancer.

Ying Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.